Questions people actually ask

Ibogaine is the main psychoactive alkaloid in the root bark of Tabernanthe iboga, a shrub from Central West Africa that is central to the Bwiti spiritual tradition of Gabon. In high doses it produces a long and intense psychedelic state. It is studied mainly as a treatment for opioid and other substance dependence. It is not an approved medicine anywhere, and it carries a real risk of fatal heart rhythm problems. Read the full introduction.

Link to this answer

Iboga is the plant, usually taken as dried root bark or an extract. It contains a mixture of alkaloids whose strength varies from batch to batch. Ibogaine is the single main alkaloid, isolated or made semi-synthetically and usually given as ibogaine hydrochloride, which allows more precise dosing. Noribogaine is what the liver turns ibogaine into, through the enzyme CYP2D6. It stays in the body far longer than ibogaine itself and is thought to contribute both to the lasting effects and to the extended period of cardiac risk.

Noribogaine is also being developed as a medicine in its own right: in April 2026 the FDA cleared the first US clinical trial of oral noribogaine.

Link to this answer

It is usually described in phases. The first hours are often dreamlike, with memories or images arising while the person lies still with eyes closed. This gives way to a long, more reflective phase, followed by a period of residual stimulation in which sleep is difficult. The acute effects commonly last 18 to 36 hours.

Nausea, vomiting and severe loss of coordination (ataxia) are common, so people cannot walk safely on their own and need someone with them throughout. Few people describe the experience as pleasant, and a period of low mood in the days afterwards is well recognised.

Link to this answer

Not without careful medical preparation, and never by stopping or switching on your own. Methadone itself prolongs the QT interval, which adds to ibogaine's main cardiac risk, and long-acting opioids stay in the body for a long time. Responsible providers therefore arrange a medically supervised switch to a shorter-acting opioid before treatment.

In a Dutch hospital study, patients on methadone or buprenorphine were first switched to morphine for exactly this reason. Even under those controlled conditions, half of them developed a QTc above 500 milliseconds after ibogaine (Knuijver and colleagues, 2022). Ask any provider exactly how they will manage your current medication, and treat a vague answer as a red flag.

Methadone and buprenorphine are effective, evidence-based treatments. Do not stop them without a plan agreed with your prescriber.

Link to this answer

Yes, and it is important to say so openly during screening. Fentanyl is now common in the street opioid supply in many places, often without people knowing. A provider can only plan the preparation safely if they know what is actually in your system. A reputable provider will ask about fentanyl directly and take it into account. Be cautious with anyone who treats it as no different from other opioids.

Link to this answer

Because tolerance can drop sharply. Ibogaine appears to reduce opioid tolerance (a Spanish hospital study found that even a low dose reduced methadone tolerance), and after any detox the body no longer handles the doses it used to. Someone who relapses and takes their previous usual amount can overdose and die. Ibogaine offers no protection against this.

If there is any chance of using again, assume your tolerance is gone, do not use alone, and keep naloxone nearby with people around you who know how to use it. This is one of the reasons aftercare matters as much as the treatment itself.

Link to this answer

This is the central risk. Ibogaine prolongs the heart's QT interval and can trigger a potentially fatal arrhythmia called torsades de pointes. Most reported deaths have involved unsupervised settings or people who were never properly screened. A baseline 12-lead ECG, correction of electrolytes, and continuous ECG monitoring are widely treated as the minimum standard (see the open-label safety study by Knuijver and colleagues, 2022). Because noribogaine stays active for a day or more, monitoring has to continue well beyond the acute experience. Read the safety guide.

Link to this answer

Common contraindications include pre-existing heart conditions, any medication that itself prolongs the QT interval, and significant liver impairment. Several antidepressants and other psychiatric medications also interact dangerously, and stopping them needs medical guidance. People whose livers process ibogaine slowly (so-called CYP2D6 poor metabolisers), or who take drugs that block that enzyme, may be exposed to higher levels.

This is not a checklist to self-assess. A responsible provider runs full cardiac and metabolic screening and will decline anyone who does not clear it. If a clinic is willing to proceed without that assessment, treat it as a red flag rather than a convenience. See the key drug interactions.

Link to this answer

Because it appears to address the main danger directly. Stanford's MISTIC protocol gave magnesium alongside ibogaine to blunt its QT prolongation and reported no cardiac complications in its cohort of veterans with traumatic brain injury. That safety framing is a large part of why the approach has drawn serious scientific attention. The study was published in Nature Medicine (2024).

Link to this answer

Costs vary widely between clinics and countries. The figure tracks programme length, the substance being treated, and above all the level of medical staffing and cardiac monitoring, not the comfort of the setting. Ask any provider for an itemised, written breakdown before paying a deposit, and be wary of a single lump-sum quote with no line for screening or monitoring. If a price looks low, check what has been left out.

Link to this answer

There is no scientific evidence that microdosing reproduces the effects studied in ibogaine research. The anti-addictive effect described in the literature involves a single large ("flood") dose given under medical supervision. Iboga carries cardiac risk at meaningful doses regardless of framing, and home use bypasses exactly the screening and monitoring that make supervised treatment safer.

Link to this answer

Look for mandatory cardiac screening, continuous ECG monitoring during and after the session, licensed medical staff physically present, honest and unprompted disclosure of the risks, a clear plan for your current medication, and reviews on independent platforms rather than testimonials hosted on the clinic's own website. The clearest warning signs are the opposite: a provider who downplays the cardiac risk, skips screening, or guarantees results. Read the guide for people considering treatment.

Link to this answer

The weeks after treatment are when much of the outcome is decided. Good aftercare is planned before treatment begins. It usually includes regular follow-up with a counsellor, therapist or integration coach, a relapse-prevention plan, support for sleep and low mood in the first days, and people at home who know what to watch for. Many clinicians consider it part of the treatment rather than an extra.

Ask any provider what they offer after you leave, for how long, and who you can call if things go badly.

Link to this answer

Only two randomised controlled trials on ibogaine for substance use disorders have ever been conducted. Observational data point to real short-term anti-addictive effects, but durable results depend heavily on integration and aftercare, and relapse is common without them. The honest summary is "promising but far from proven", which is why the current wave of state-funded trials matters. Read the evidence summary.

Link to this answer

Because those figures are almost always marketing, not research. Numbers like "90%+ resolution" typically come from a clinic's own website, self-reported and unaudited, sometimes "medically reviewed" by that same clinic's director. Genuine evidence is published in peer-reviewed journals and registered on ClinicalTrials.gov, where outcomes are far more modest and the caveats are stated openly. A useful rule: if a success rate isn't attached to a citation you can check, treat it as an advertisement.

Link to this answer

There are encouraging early signals, but no controlled trials yet. The best-known study, from Stanford, treated 30 US special operations veterans with traumatic brain injury using ibogaine combined with magnesium, at a clinic in Mexico. One month later, participants reported large improvements in disability, PTSD, depression and anxiety (Nature Medicine, 2024).

The study had no control group and participants knew what they were receiving, so placebo and expectation effects cannot be ruled out. Evidence for depression on its own is very limited. The trials now being set up in Texas and Colorado should begin to answer these questions properly.

Link to this answer

Ibogaine is Schedule I in the United States. In Canada (since 2017), New Zealand, Australia and South Africa it is a prescription-only medicine, although it is not an approved treatment in any of them. It is a controlled drug in France, Belgium, Denmark and several other European countries. In the Netherlands and Germany it is not on the narcotics lists, but it is not an approved medicine either. Clinics operate in Mexico, the Netherlands, South Africa, Costa Rica and elsewhere, often in legal grey areas. See the country-by-country overview.

Link to this answer

No. Ibogaine remains a Schedule I controlled substance under US federal law. The April 2026 executive order directs federal agencies, including the FDA, to speed up research and regulatory review, to explore access under Right to Try, and to support state research funding. Rescheduling would still require clinical evidence and formal regulatory action. In practice, the legal routes to ibogaine in the US today are clinical trials and state research programmes such as those in Texas and Colorado.

Link to this answer

Netherlands: ibogaine is not listed under the Opium Act, so possession is not a criminal offence. It is not an approved medicine, and providers work in a legal grey area with widely varying standards. Clinical research is possible: the safety study by Knuijver and colleagues was carried out at Dutch addiction clinics.

Germany: ibogaine is not listed in the narcotics law (Betäubungsmittelgesetz), but it is not an approved medicine either. Doctors cannot treat patients with it outside research, and offering it as a treatment sits in a legal grey area.

Belgium: ibogaine is a controlled substance.

Laws change, so check the current rules where you live. See the full legal overview.

Link to this answer

It is a real concern. Iboga is a slow-growing shrub, the medicine comes from its root bark, and rising international demand has put pressure on wild plants in Central Africa. Gabon, home of the Bwiti tradition, regulates export to protect the plant and the communities who depend on it. Much of the ibogaine used today is made semi-synthetically from voacangine, an alkaloid found in a related and more plentiful plant, Voacanga africana.

Newer regulation is starting to address this. Colorado's 2026 law ties ibogaine sourcing to the Nagoya Protocol, the international agreement on sharing benefits with source communities.

Link to this answer